Applied Filters
Astellas doubles down on gene therapy with $3bn Audentes deal
Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Merck KGaA secures CRISPR patents in Japan and Singapore
The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.
Chinese state-owned chemical firm in fungicide patent suit
A Chinese state-owned chemical firm is suing US crop protection products company Atticus for patent infringement.
Novartis takes aim at Indian drug companies over Entresto generics
Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
Philippines IP office issues warning over fake drugs
The Philippines’ deputy IP chief has warned e-commerce platforms that they could be made liable for the sale of counterfeit goods on their sites under new legislation, amid fears over the spread of counterfeit pharmaceuticals.
Insilico Medicine signs $200m AI drug discovery deal
Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
US biotech licenses antibody from Takeda for new kidney drugs
Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 antibody from Japanese pharmaceutical manufacturer Takeda.
Taiwanese firm accuses Pacific Biosciences of infringing sequencing tech
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement.
Taiwanese biotech abandons drug R&D under Genentech MoU
Taiwanese company JHL Biotech will stop developing biosimilar versions of Genentech’s drugs as part of a memorandum of understanding signed by the parties to end trade secrets litigation.
Lupin and Boehringer enter $720m anti-cancer drug partnership
Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.
